The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...

Novo Nordisk (NYSE: NVO) hasn't been getting much love on Wall Street. The stock trades down 66% from its 2024 highs and just took a big hit after the company offered weak guidance for 2026. However, ...

Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

COPENHAGEN, Denmark — Novo Nordisk sued Hims and Hers Health on Monday over alleged patent infringement after the U.S. telehealth firm launched, then canceled, a $49 copy of Novo's weight-loss pill ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Novo on Monday argued ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knockoffs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...

Hims & Hers (HIMS) on Monday called a patent lawsuit filed by Novo Nordisk (NVO) over IP rights linked to the Danish drugmaker’s weight loss therapy, semaglutide, “a blatant attack” targeting ...

Novo shares rise 5% after Hims scraps $49 weight‑loss pill FDA signals broader crackdown on compounded GLP-1 drugs Hims pulled its semaglutide-based pill after pushback Hims says lawsuit attacks ...

Novo Nordisk conquered the world with its borderline miraculous drug semaglutide, sold as Ozempic and Wegovy. But with a sinking stock price and compelling alternatives eating its lunch, it’s now ...

Novo Nordisk shares rallied on Friday in what’s still been a painful week as the Food and Drug Administration may weigh in on the side of the Danish drugmaker in its dispute over a copycat drug. Novo ...